KRAS and neoplasm: Clinically, KRAS-mutant tumors with STK11/KEAP1 inactivation are known to be less responsive to immune checkpoint inhibitors and often exhibit a “cold” tumor immune microenvironment (low PD-L1, Programmed Death-Ligand 1, with low T-cell infiltration), [13].